United States - English - NLM (National Library of Medicine)

atland pharmaceuticals, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative  treatment options [e.g., non-opioidanalgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine and dihydrocodeine bitartrate tablets are contraindicated for: all - children younger than 12 years of age [see  warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see  warnings and precau

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - dihydrocodeine tartrate - oral tablet - 30mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

daiichi sankyo company, limited - dihydrocodeine phosphate - white to yellowish white powder

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

daiichi sankyo company, limited - dihydrocodeine phosphate - white to yellowish white powder

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

daiichi sankyo company, limited - dihydrocodeine phosphate - white to yellowish white powder

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - dihydrocodeine phosphate - white powder

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

noripharma sdn. bhd. - dihydrocodeine tartrate -

United States - English - NLM (National Library of Medicine)

wraser llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 320.5 mg - trezix™ (acetaminophen, caffeine, and dihydrocodeine bitartrate) capsules are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve trezix™ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia trezix™ is contraindicated for: - all children younger than 12 years of age [see warnings and precautions] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and precautions]. - trezix​tm ​ is also contraindicated in patients with: - significant respiratory depression [see warnings] - acute or severe bronchial asthma in an unmonitored setting

Malta - English - Medicines Authority

napp pharmaceuticals limited cambridge science park, milton road, cambridge, cb4 0gw, united kingdom - dihydrocodeine tartrate - prolonged-release tablet - dihydrocodeine tartrate 60 mg - analgesics

United States - English - NLM (National Library of Medicine)

xspire pharma, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 320.5 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate capsules are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine, and dihydrocodeine bitartrate is contraindicated for: - all children younger than 12 years of age [see warnings and precautions] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and precautions]. acetaminophen, caffeine, and dihydrocodeine bitartrate is also contraindicated in pati